StockNews.AI
MRNA
StockNews.AI
207 days

Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union

1. Moderna secures a 4-year mRNA vaccine supply tender across 17 EU nations. 2. This agreement enhances access to pre-filled syringe vaccine formats for participating countries.

2m saved
Insight
Article

FAQ

Why Bullish?

The contract reinforces Moderna's market position in the EU, possibly boosting revenues, similar to past vaccine agreements.

How important is it?

The tender directly influences Moderna's sales and strategic expansion in Europe.

Why Long Term?

The four-year agreement solidifies future revenue streams and market presence in Europe.

Related Companies

BNTXPFENVAX
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years.

Related News